Transforming growth factor-β1 enhances the invasiveness of breast cancer cells by inducing a Smad2-dependent epithelial-to-mesenchymal transition

ZHI-DONG LV1, BIN KONG1, JIAN-GUO LI1, HUI-LI QU1, XIN-GANG WANG1, WEI-HONG CAO1, XIAO-YI LIU1, YU WANG1, ZHAO-CHUAN YANG2, HUI-MIAN XU3 and HAI-BO WANG1

Departments of 1Breast Surgery and 2Child Health Care, The Affiliated Hospital of Qingdao University Medical College, Qingdao 266003; 3Department of Surgical Oncology, The First Hospital of China Medical University, Shenyang 110001, P.R. China

Received July 1, 2012; Accepted August 28, 2012

DOI: 10.3892/or.2012.2111

Abstract. Metastasis is unequivocally the most lethal aspect of breast cancer and the most prominent feature associated with disease recurrence, the molecular mechanisms whereby epithelial-to-mesenchymal transition (EMT) mediates the initiation and resolution of breast cancer metastasis remains poorly understood. Transforming growth factor-β1 (TGF-β1) is a multifunctional cytokine that is intimately involved in regulating numerous physiological processes, including cellular differentiation, homeostasis and EMT. Recent findings have implicated high levels of TGF-β1 were associated with poor outcome, whereas inhibition of TGF-β signaling reduces metastasis in breast cancer, suggesting that the chemotherapeutic targeting of TGF-β1 or TGF-β signaling may offer new inroads in ameliorating metastatic disease in breast cancer patients. In this study, we showed immunohistochemical evidence for EMT, which is associated with TGF-β1 expression, at the invasion front of breast cancer in vivo. The data also indicated that human breast cancer cell lines, MCF-7 and MDA-MB435S, of epithelial cell characteristics were induced to undergo EMT by TGF-β1 and dependent on the Smad2 signaling pathway. Following TGF-β1 treatment, cells showed dramatic morphological changes assessed by phase contrast microscopy, accompanied by decreased epithelial marker and increased mesenchymal markers. Importantly, cell invasion was also enhanced in the EMT process, while knockdown of the Smad2 gene by silencing siRNA partially inhibited these effects in MDA-MB435S (P<0.05). These data suggested that EMT of breast cancer induced by TGF-β1 is dependent on Smad2 signaling and promotes breast cancer cell metastasis.

Introduction

Breast cancer is one of the major causes of death in women, ~350,000 women die from breast cancer each year (1). However, most mortality and morbidity does not arise from the primary tumor, but from distant metastasis (2). In order to metastasize a cancer cell must shed many of its epithelial characteristics, invade the surrounding tissue to enter the circulation, subsequently survive in the circulation, extravasate and proliferate in the metastatic niche (3). Invasion is therefore a key step in the metastatic cascade. Targeted therapy for metastatic disease is clinically unavailable because the molecular mechanism underlying metastasis remains unclear (4). Thus, identifying functional metastasis genes and their molecular mechanisms underlying the metastatic process remains a top priority in the cancer research field.

Recent research has demonstrated that epithelial-to-mesenchymal transition (EMT) plays a key role in the early process of metastasis of cancer cells (5). Greenburg and Hay (6) first described that epithelial cells cultured in vitro might acquire mesenchymal features, providing the proof of principle for the process of EMT. The transition of epithelial cells into mesenchymal cells, known as EMT, is a process during which cells undergo a morphological switch from the epithelial polarized phenotype to a highly motile fibroblastic or mesenchymal phenotype (7). In the EMT process, epithelial cells lose their features, gain mesenchymal properties, and become motile and invasive. The feature of EMT is the reduction of cell-cell adhesion, especially the reduction of E-cadherin which is critical to maintain the epithelial structure. It has been reported that the loss of E-cadherin expression is correlated with tumor invasion and metastasis (8). With the loss of E-cadherin expression, the expression of mesenchymal markers, vimentin and fibronectin, can be upregulated when EMT occurs (7,9).
Transforming growth factor-β1 (TGF-β1) signals have an important role in the metastatic spread of cancer cells, such as migration, invasion, and EMT (7,10,11). Overexpression of TGF-β1 is reported to be correlated with poor prognosis of breast tumours, especially basal-like and luminal type of cancers, suggesting that TGF-β signaling might have an important role in the progression of breast cancer cells (12,13). Therefore, inhibition of TGF-β signaling in breast carcinoma may yield beneficial effects through inhibition of invasion and metastasis of cancer. TGF-β1 mediates EMT by inducing Smad signaling (7,14,15). Smads are a group of intracellular proteins that are critical for transmitting the TGF-β1 signals from the cell surface to the nucleus in order to promote transcription of target genes (16). The role of Smad3 in the development of EMT has been reported (17,18). However, the potential role of Smad2 in the development of EMT is unclear.

To understand the role of EMT in breast cancer metastasis and its mechanism, we demonstrated in this study that TGF-β1 induced a series of EMT-associated changes in breast cancer is dependent on the Smad2 signaling and promoted tumor progression and metastasis by means of EMT.

Materials and methods

Reagents. Total Smad2, phosphorylated Smad2, α-SMA, vimentin, cytokeratin, TGF-β1 and E-cadherin antibodies, as well as secondary antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The transwell chamber was obtained from Corning Life Sciences (NY, USA). DMEM and fetal calf serum were purchased from Gibco-BRL (Carlsbad, CA, USA). Human TGF-β1 was obtained from Sigma (St. Louis, MO, USA). Other laboratory reagents were obtained from Sigma.

Cell line and culture. Two human breast cancer cell lines, MCF-7 and MDA-MB-435S, were obtained from the Cancer Research Institute of Beijing, China. These cells were cultivated in T75 tissue culture flasks in DMEM supplemented with 10% fetal calf serum, 100 IU/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, and 20 mM hydroxyethyl piperazine ethanesulfonic acid, and incubated in a humidified incubator containing 5% CO₂, at 37°C.

Tissue immunohistochemistry and scoring. Breast tumor samples from 128 patients who underwent surgery in the Affiliated Hospital of Qingdao University Medical College between March 2011 and October 2011, were studied. The local institutional review board approved our protocol for use of patient samples; all patients provided written informed consent prior to participation in the study. Three 5-µm sections of these seeds were then cut. An additional H&E section was stained, and the remaining sections were used for immunohistochemistry. Tissue was fixed with acetone for 10 min and rehydrated with ethanol. Slides were blocked with 10% horse serum for 1 h at room temperature and incubated with cytokeratin (1:50), E-cadherin (1:100), vimentin (1:200), and TGF-β1 (1:50) antibodies overnight at 4°C. Slides were incubated with anti-mouse biotinylated secondary antibody (1:200). Finally, detection was carried out with the DAB kit according to the manufacturer’s instructions. Each slide had at least three replicate sections for each antibody. Quantitative analysis of cytokeratin and vimentin staining in the central tumor area compared with the invasive margin was done by two independent observers. The invasive front was identified and the area of central tumor most distant from this invasive front was then selected, and three independent fields were scored for staining intensity and for cellular localization of cytokeratin staining. The intensity of staining was scored as 0 (none), 1 (weak), 2 (mild), 3 (moderate), and 4 (strong) compared with a negative (no primary antibody) and positive control. The cellular localization of cytokeratin was classified as membranous, cytoplasmic or mixed.

Phase contrast microscopy. The phenotypic changes of breast cancer cells were determined by phase contrast microscopy. The cancer cells in cultures treated with recombinant TGF-β1 and left untreated (control) for 72 h and morphological changes were visualized by phase contrast microscopy. The images were collected using Nikon inverted microscope.

Western blot analysis. Breast cancer cells were cultured on a 6-well tissue culture plate to confluence. The cell were treated with recombinant human TGF-β1 at the time of switching to serum-free medium, at a final concentration of 5 ng/ml. The cancer cells cultured without TGF-β1 were considered as control. The cells were harvested at 72 h. Total cellular protein was extracted using a lysis buffer and quantified using protein quantification reagents from Bio-Rad. Next, 60 µg of the protein was suspended in 5X reducing sample buffer, boiled for 5 min, electrophoresed on 10% SDS-PAGE gels, and then transferred to polyvinylidene difluoride membrane by electroblotting. The membrane was blocked in 1% BSA/0.05% Tween/PBS solution overnight at 4°C, followed by incubation with the primary antibody (mouse monoclonal antibodies to either human α-SMA, vimentin, cytokeratin, E-cadherin, phosphorylated-Smad2, or Smad2) for 24 h. A horseradish peroxidase-labelled goat anti-mouse IgG was used as the secondary antibody. The blots were then developed by incubation in a chemiluminescence substrate and exposed to X-ray film.

Small interfering-RNA (siRNA) treatment. The breast cancer cells were grown to a 70% confluence on culture dishes and the transient transfection was performed with specific stealth small interference RNA against Smad2, or control siRNA over-
night using Lipfectamine-2000, according the manufacturer’s instructions. The total of two siRNA sequences for Smad2 and control-siRNA were designed and synthesized from Invitrogen using RNAi designer software program. The concentration of 300 nM was determined to be the most effective siRNA concentration for Smad2 silencing. The transfection medium was changed with culture medium containing 5% FBS for 24 h. TGF-$\beta_1$ at final concentration of 5 ng/ml was added to the cell cultures in serum-free medium or without TGF-$\beta_1$ (control). The cells were harvested at 4, 24 and 72 h for further experiments.

Invasion assay. In vitro invasiveness was measured by the method described in the study by Albini et al (19), with some modifications. We used chemotaxis chambers with a 8 µm-pore membrane filter coated with 50 mg of matrigel in a 24-well culture plate. MDA-MB-435S cells were pretreated with TGF-$\beta_1$ or Smad2-siRNA, and plated at a concentration of $3 \times 10^5$/ml per upper well in 200 µl of serum-free medium. As a chemoattractant, 10% fetal calf serum medium was used in the lower chamber. After being recultured with 5% CO$_2$ at 37°C for 24 h, the filters were removed, fixed in 95% alcohol, and stained with trypan blue. The cells remaining on the top surface of the membrane were completely removed with a cotton swab, and the membrane was removed from the chamber and mounted on a glass slide. The number of infiltrating cancer cells were counted in five regions selected at random, and the extent of invading cancer cells was determined by the mean count.

Statistical analysis. All values in the text and figures are presented as mean ± SD. In univariate analysis, 2-tailed $\chi^2$ tests for categorical variables and 2-tailed t-test for continuous variables were used for statistical comparisons. Values of P<0.05 were taken to show a significant difference between means.

Results

Increased expression of mesenchymal markers at invasion front. Immunohistochemical analysis of the invasive component of carcinoma specimens was compared with the central area of the tumor. There was downregulation of the intensity of the epithelial staining with E-cadherin and cytokeratin at the

Figure 1. Cytokeratin, E-cadherin, vimentin and TGF-$\beta_1$ expression at the the central tumor area and invasive margin. (A) Representative immunohistochemical staining for cytokeratin, E-cadherin, vimentin and TGF-$\beta_1$. i) Tumor containing the invasive margin at low-power image (magnification, x100) with representative high-power images (magnification, x100). Black frames, areas selected from the low-power field show ii) the central tumor area and iii) invasive margin. (B) Quantitative assessment of immunohistochemistry for intensity of cytokeratin (white columns) and vimentin (black columns) staining of the central tumor compared with the invasive margin. *P<0.05 as compared the central tumor with the invasive margin for the same marker.
invasive tumor margin. Furthermore, there was a redistribution of E-cadherin staining from a predominantly membranous pattern in the central area to a predominantly cytoplasmic pattern at the margin. In contrast, a low intensity of vimentin staining was observed in the center of the tumor compared with increased intensity of expression at the invasive margin. Quantification of cytokeratin and vimentin staining intensity showed downregulation of cytokeratin at the invasive margin (P<0.005) and a contrasting upregulation of vimentin staining (P<0.05). Staining for TGF-β1 showed a predominantly stromal expression pattern in both the central and invasive tumor components with foci of increased uptake in the invasive front (Fig. 1).

Morphological changes of breast cancer cells. In the absence of TGF-β1, small portions of cell morphology were somewhat mesenchymal, but most breast cancer cells showed pebble-like shape and tight cell-cell adhesion. However, after TGF-β1 treatment for 72 h, MCF-7 and MDA-MB-435S cells showed morphological changes assessed by phase contrast microscopy. Many cells assumed more elongated shape and lost contact with their neighbor, displaying fibroblast-like appearance compared to the untreated cells (Fig. 2).

TGF-β1 induces EMT marker changes in breast cancer cells. To better confirm morphological changes in breast cancer cells, MCF-7 and MDA-MB-435S cells, represent EMT, western blotting was used to examine the changes of EMT-related protein markers. The results indicated that the expression of cytokeratin and E-cadherin, the epithelial phenotype marker, was significantly decreased in MDA-MB-435S cells, while TGF-β1 did not affect the E-cadherin expression levels in MCF-7. Those of mesenchymal phenotype markers, α-SMA and vimentin, were greatly increased in MCF-7 and MDA-MB-435S cells (Fig. 3).

Effects of TGF-β1 or siRNAi-Smad2 on Smad2 phosphorylation of breast cancer cells. Here we showed that Smad2 phosphorylation was increased by TGF-β1 in MCF-7 and MDA-MB-435S, while TGF-β1 did not affect the total Smad2 expression levels. In order to confirm whether Smad2 is involved in TGF-β1 mediated EMT of breast cancer, siRNAs were used to knockdown the Smad2 gene in MDA-MB-435S. As shown in Fig. 4B, siRNAi-Smad2#1 highly significant knockdown for Smad2 and phosphorylated Smad2 when compared to the other siRNAs or the control.
Silencing Smad2 signaling blocks TGF-β1-induced mesenchymal transformation in MDA-MB-435S. After silencing Smad2 by using siRNA-Smad2 or control-siRNA in cancer cells treated with TGF-β1, we noted a remarkably reduced expression of vimentin, and most importantly a significant restoration of the junctional protein cytokeratin suggesting a role for Smad2 signaling in EMT of cancer cells (Fig. 5).

Promotion of cell invasion induced by TGF-β1. We analyzed the invasion capability of the highly metastatic MDA-MB-435S cells using the methods described above. The results showed that TGF-β1 significantly promoted the invasiveness of cells when compared to control (P<0.05). While Smad2-siRNA significant decreased the number of invasive cells under TGF-β1 stimulation (P<0.05). These results suggested EMT of breast cancer induced by TGF-β1 promote cancer cells metastasis, but knockdown of the Smad2 gene, by silencing siRNA reduced the invasion of gastric cancer cells can partially inhibit these effects (Fig. 6).

Discussion

In this study, we showed immunohistochemical evidence for EMT, which is associated with TGF-β1 expression at the invasion front of breast cancer in vivo. A TGF-β1-induced in vitro model of EMT showed morphologic, molecular, and functional evidence for this process that was reversible by Smad2 RNAi.

The differential expression of epithelial and mesenchymal markers has been recognized in several rare tumors of mixed phenotype (20,21). More recently, this differential expression of epithelial and mesenchymal markers at the invasive margin has been described in colorectal and hepatocellular tumors (22,23), suggesting that EMT might be a feature of the invasive characteristics of epithelial tumors. In addition, changes suggestive of EMT have been described in cell lines, such as nonmalignant Madin-Darby canine kidney cells, and cell lines derived from the pancreas cancers (24).
The molecular and phenotypic changes from an epithelial to a mesenchymal cell type seem to be functionally relevant because several studies have shown that EMT is important in cancer progression (25,26). During EMT, epithelial cell-cell contact is decreased by the downregulation of cytoskeletal components and the cell morphology becomes more fibroblast-like with upregulation of mesenchymal markers, including α-SMA and vimentin (27,28). Loss of the classic epithelial marker E-cadherin is associated with poor outcome in several tumor sites, including invasive ductal breast carcinoma (29), and gastric adenocarcinoma (30). A reduction in E-cadherin level is considered as a hallmark of EMT. E-cadherin plays a key role in maintaining the epithelial structural integrity and polarization, loss of which consequently destabilizes the structural integrity of epithelium and makes cells dissociate from their neighbors (31). Our data demonstrated that breast cancer cells undergo transition from the epithelial to the mesenchymal phenotype upon activation with TGF-β1, with the induction of the transcription factor Smad2 and the expression changes of EMT-related proteins occurred in MDA-MB-435S. However, the E-cadherin expression did not change in MCF-7. We concluded that MDA-MB-435S, but not MCF-7, was prone to undergo a complete EMT. EMT may contribute to greater motility and higher invasiveness of tumor cells.

Smads are a group of intracellular proteins that are critical for transmitting the TGF-β1 signals from the cell surface to the nucleus to promote transcription of target genes (14,16). Accumulating evidence indicates that TGF-β stimulates cancer cell EMT and metastasis through a combination of Smad2/3-dependent and -independent signaling systems. Engineering metastatic human MCF10A/CaA1a breast cancer cells to express a dominant-negative Smad3, or a TβR-I mutant incapable of activating Smad2/3, significantly reduced the ability of MCF10A/CaA1a cells to colonize the lung (32). In the present study, we demonstrated the role of Smad2 in TGF-β1-mediated EMT in MDA-MB-435S. The significance of the present study is that breast cancer cells undergo the process of EMT via expression of the mesenchymal markers vimentin and α-SMA, and siRNA-Smad2 significantly blocked the expression of vimentin in cancer cells activated with TGF-β1 and prevented EMT.

In the context of epithelial cancer, EMT provides a mechanism for tumor cells to leave the primary tumor and invade into the local tissue and blood vessels, setting the stage for metastatic spread (33). Therefore, EMT is hypothesized to contribute to tumor progression, and indeed clinical evidence suggests that regulators of EMT, such as TGF-β1, in cancer cells correlate with poor patient outcomes and tumor aggressiveness (13,34). To evaluate these biological functions of the cells undergoing EMT and if Smad2 siRNA could reduce this ability of invasion, we used invasion assays in our study. Our results showing cells undergoing EMT, which was demonstrated by changes in cell morphology, cell behavior, and expression of EMT-related protein markers, whereas knockdown of the Smad2 gene by silencing siRNA partially inhibited these effects. Collectively, our current data demonstrated that EMT of breast cancer induced by TGF-β1 is dependent on Smad2 signaling and promotes breast cancer cell metastasis.

References